Gain Therapeutics, Inc.
GANX
$1.73
$0.021.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.59M | -20.93M | -20.41M | -21.37M | -21.60M |
| Total Depreciation and Amortization | 37.90K | 38.20K | 37.00K | 39.30K | 37.20K |
| Total Amortization of Deferred Charges | 48.00K | 46.00K | 47.00K | 47.00K | 48.00K |
| Total Other Non-Cash Items | 2.95M | 3.07M | 2.53M | 2.04M | 2.46M |
| Change in Net Operating Assets | -2.90M | -1.34M | -1.08M | -1.84M | 81.50K |
| Cash from Operations | -18.45M | -19.11M | -18.87M | -21.08M | -18.97M |
| Capital Expenditure | -900.00 | -22.40K | -22.40K | -21.50K | -22.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.50K | 1.98M | 5.00M | 8.18M | 10.11M |
| Cash from Investing | -43.40K | 1.96M | 4.98M | 8.16M | 10.09M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -92.30K | -90.20K | -90.90K | -90.70K | -90.20K |
| Issuance of Common Stock | 8.08M | 15.65M | 13.38M | 20.63M | 19.96M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -280.90K | -280.90K | -280.90K |
| Cash from Financing | 7.99M | 15.56M | 13.01M | 20.26M | 19.59M |
| Foreign Exchange rate Adjustments | 271.80K | 24.80K | -527.20K | 436.60K | -90.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.24M | -1.57M | -1.41M | 7.78M | 10.62M |